Manufacturing and Production

Showing 15 posts of 5863 posts found.

Bayer to cut 12,000 jobs by 2025

December 6, 2018 Business Services, Manufacturing and Production, Sales and Marketing Bayer, Germany, Jobs, manfucaturing, monsanto, production

German pharma giant Bayer is set to cut 12,000 jobs by 2025 as part of a plan to focus on …

Sanofi announce cull of 670 French jobs

December 6, 2018 Business Services, Manufacturing and Production CGT, France, Jobs, Macron, Sanofi, gilet jaunes, yellow jackets

French pharma giant Sanofi has said that it will cut 670 jobs in France over the next two years. The …

Working Life: Kai Gait, Senior Global Digital Director at GlaxoSmithKline

December 6, 2018 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EU, GSK, Interview, UK, US, digital, senior global director, technology

Kai Gait, Senior Global Digital Director at GlaxoSmithKline, retraces the steps that have led him to where he is today, …

NICE approves Cimzia but blocks Ilumetri in treatment of psoriasis

December 4, 2018 Manufacturing and Production, Sales and Marketing Almirall, Cimzia, Ilumetri, NICE, UCB, UK, pharma, psoriasis

UK drug watchdog NICE has announced two new recommendations relating to medicines for the treatment of psoriasis, approving UCB Pharma’s …

Pfizer’s biosimilar proves non-inferior to rituximab in lymphoma at ASH 2018

December 4, 2018 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ASH 2018, Pfizer, haemophilia

Joining the chorus of data presentations at the American Society of Hematology (ASH) Annual Meeting 2018, Pfizer has announced new …
shutterstock_243110086

Hemlibra shows “clinically meaningful” bleed control in paediatric haemophilia A patients

December 4, 2018 Manufacturing and Production, Research and Development ASH 2018, Hemlibra, Roche, haemophilia, pharma

In another reveal at the American Society of Hematology (ASH) Annual Meeting 2018, Roche unveiled new Phase 3 findings for …
institute_of_cancer_research

Cancer drug access for NHS patients is slowing, ICR reports

December 4, 2018 Manufacturing and Production, Research and Development, Sales and Marketing Cancer, ICR, Institute of Cancer Research, NHS, NICE, UK, pharma

A new report from the Institute of Cancer Research (ICR) has indicated that NHS patients in the UK are suffering …
roche

Roche chooses Veeva Vault PromoMats for digital asset management and content

December 4, 2018 Manufacturing and Production, Medical Communications Roche, pharma, veeva

Today, at the 2018 Veeva Commercial & Medical Summit Europe, Roche (SWX:ROG) announced that it would be adopting Veeva Systems …
shutterstock_87495637

Pegfilgrastim greenlight marks eighth biosimilar approval in Europe for Sandoz

November 27, 2018 Manufacturing and Production, Sales and Marketing Amgen, Neulasta, Sanofi, Ziextenzo, biosimilars, pegfilgrastim, pharma

The European Commission has chosen to grant marketing authorisation to Ziextenzo, Sandoz’s biosimilar version of pegfilgrastim, better known as Amgen’s …
stocks1

Phase 3 failure of asthma therapy sends Vectura’s ailing shares falling

November 27, 2018 Manufacturing and Production, Research and Development asthma, pharma, trial failure, vectura

Vectura has announced it is terminating development of its severe asthma therapy VR475, an inhaled formulation of the corticosteroid budesonide, …
nhs_sign

NHS to save £300 million by switching to Humira biosimilars

November 27, 2018 Manufacturing and Production, Sales and Marketing AbbVie, Humira, Mylan, NHS, Sandoz, adalimumab, biosimilars, pharrma

NHS England has announced that the health service is set to save £300 million by switching to biosimilar versions of …
bmssyracuseny

BMS’ Opdivo+Yervoy combo fails in small cell lung cancer

November 27, 2018 Manufacturing and Production, Research and Development Bristol-Myers Squibb, Cancer, Yervoy, lung cancer, opdivo, pharma

Bristol-Myers Squibb has revealed that its combo comprising Opdivo (nivolumab) and Yervoy (ipilimumab) failed to meet its primary endpoint as …
fda2outsideweb

FDA approves first oral TRK inhibitor with Loxo Oncology’s Vitrakvi

November 27, 2018 Manufacturing and Production, Sales and Marketing Cancer, FDA, Loxo Oncology, Vitrakvi, oncology, pharma

The FDA has announced the approval of the United States’ first-ever oral tyrosine kinase (TRK) inhibitor, Loxo Oncology’s Vitrakvi (larotrectinib), …
The Gateway to Local Adoption Series

Latest content